SR One Capital Management, LP 13F holdings
SR One Capital Management, LP reported 15 positions with a total reported value of $1.0B as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-12. Top holdings by reported value: MANE Veradermics, Inc. (28.4%), ZBIO Zenas BioPharma, Inc (12.3%), CRSP CRISPR Therapeutics AG (10.7%), AVLN Avalyn Pharma, Inc (10.5%), DSGN Design Therapeutics, Inc. (9.1%). Against 2026-03-31 it opened 3 new positions and exited 2. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when SR One Capital Management, LP files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
15 largest of 15 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| MANE Veradermics, Inc. | 2,401,868 | $295.3M | 28.4% |
| ZBIO Zenas BioPharma, Inc | 5,037,854 | $127.9M | 12.3% |
| CRSP CRISPR Therapeutics AG | 2,038,763 | $111.2M | 10.7% |
| AVLN Avalyn Pharma, Inc | 3,308,649 | $108.9M | 10.5% |
| DSGN Design Therapeutics, Inc. | 6,526,476 | $94.4M | 9.1% |
| ODTX Odyssey Therapeutics, Inc. | 3,794,883 | $71.0M | 6.8% |
| ALMS Alumis Inc. | 1,959,896 | $55.2M | 5.3% |
| ORIC ORIC Pharmaceuticals, Inc. | 4,615,384 | $50.0M | 4.8% |
| MLYS Mineralys Therapeutics Inc. | 1,563,966 | $42.2M | 4.1% |
| SPRY ARS Pharmaceuticals, Inc. | 4,012,903 | $32.1M | 3.1% |
| MOBI Mobia Medical, Inc | 1,986,072 | $26.6M | 2.6% |
| NKTX Nkarta, Inc. | 3,333,333 | $9.4M | 0.9% |
| OCS Oculis Holding AG | 641,022 | $8.9M | 0.9% |
| RARE Ultragenyx Pharmaceutical Inc. | 137,753 | $4.6M | 0.4% |
| ENGN enGene Holdings Inc. | 747,750 | $1.3M | 0.1% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 3 in all · reported value as of 2026-06-30
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 2 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| Arcellx, Inc. | 2,346,630 | $269.4M | 29.4% |
| ORKA Oruka Therapeutics, Inc | 430,330 | $21.1M | 2.3% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| ORIC ORIC Pharmaceuticals, Inc. | 4,514,929 | 4,615,384 | +2.2% | $50.0M |
Decreases
No position was decreased.
CIK 1910264 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
